208 related articles for article (PubMed ID: 32382128)
1. Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis.
Chuang YM; He L; Pinn ML; Tsai YC; Cheng MA; Farmer E; Karakousis PC; Hung CF
Cell Mol Immunol; 2021 Oct; 18(10):2393-2401. PubMed ID: 32382128
[TBL] [Abstract][Full Text] [Related]
2. Role of Granulocyte-Macrophage Colony-Stimulating Factor Production by T Cells during
Rothchild AC; Stowell B; Goyal G; Nunes-Alves C; Yang Q; Papavinasasundaram K; Sassetti CM; Dranoff G; Chen X; Lee J; Behar SM
mBio; 2017 Oct; 8(5):. PubMed ID: 29066547
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis.
Zhang Y; Liu J; Wang Y; Xian Q; Shao L; Yang Z; Wang X
Sci China Life Sci; 2012 Sep; 55(9):800-6. PubMed ID: 23015129
[TBL] [Abstract][Full Text] [Related]
4. GM-CSF Dependent Differential Control of
Mishra A; Singh VK; Actor JK; Hunter RL; Jagannath C; Subbian S; Khan A
Front Immunol; 2020; 11():1599. PubMed ID: 32793233
[TBL] [Abstract][Full Text] [Related]
5. Keratinocyte growth factor administration attenuates murine pulmonary mycobacterium tuberculosis infection through granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent macrophage activation and phagolysosome fusion.
Pasula R; Azad AK; Gardner JC; Schlesinger LS; McCormack FX
J Biol Chem; 2015 Mar; 290(11):7151-9. PubMed ID: 25605711
[TBL] [Abstract][Full Text] [Related]
6. Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs.
Ryan AA; Wozniak TM; Shklovskaya E; O'Donnell MA; Fazekas de St Groth B; Britton WJ; Triccas JA
J Immunol; 2007 Dec; 179(12):8418-24. PubMed ID: 18056388
[TBL] [Abstract][Full Text] [Related]
7. Human Macrophages Exhibit GM-CSF Dependent Restriction of
Mishra A; Singh VK; Jagannath C; Subbian S; Restrepo BI; Gauduin MC; Khan A
Front Immunol; 2022; 13():859116. PubMed ID: 35634283
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection.
Nambiar JK; Ryan AA; Kong CU; Britton WJ; Triccas JA
Eur J Immunol; 2010 Jan; 40(1):153-61. PubMed ID: 19830735
[TBL] [Abstract][Full Text] [Related]
10. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
11. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection.
Gonzalez-Juarrero M; Hattle JM; Izzo A; Junqueira-Kipnis AP; Shim TS; Trapnell BC; Cooper AM; Orme IM
J Leukoc Biol; 2005 Jun; 77(6):914-22. PubMed ID: 15767289
[TBL] [Abstract][Full Text] [Related]
12. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
13. Development of an extended half-life GM-CSF fusion protein for Parkinson's disease.
Yeapuri P; Olson KE; Lu Y; Abdelmoaty MM; Namminga KL; Markovic M; Machhi J; Mosley RL; Gendelman HE
J Control Release; 2022 Aug; 348():951-965. PubMed ID: 35738463
[TBL] [Abstract][Full Text] [Related]
14. Haemopoiesis in mice genetically lacking granulocyte-macrophage colony stimulating factor during chronic infection with Mycobacterium avium.
Zhan Y; Cheers C
Immunol Cell Biol; 2000 Apr; 78(2):118-23. PubMed ID: 10762411
[TBL] [Abstract][Full Text] [Related]
15. Alcohol impairs recognition and uptake of Mycobacterium tuberculosis by suppressing toll-like receptor 2 expression.
Wigger GW; Khani D; Ahmed M; Sayegh L; Auld SC; Fan X; Guidot DM; Staitieh BS
Alcohol Clin Exp Res; 2022 Dec; 46(12):2214-2224. PubMed ID: 36281822
[TBL] [Abstract][Full Text] [Related]
16. Relative levels of M-CSF and GM-CSF influence the specific generation of macrophage populations during infection with Mycobacterium tuberculosis.
Higgins DM; Sanchez-Campillo J; Rosas-Taraco AG; Higgins JR; Lee EJ; Orme IM; Gonzalez-Juarrero M
J Immunol; 2008 Apr; 180(7):4892-900. PubMed ID: 18354213
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis.
Francisco-Cruz A; Mata-Espinosa D; Ramos-Espinosa O; Marquina-Castillo B; Estrada-Parra S; Xing Z; Hernández-Pando R
Tuberculosis (Edinb); 2016 Sep; 100():5-14. PubMed ID: 27553405
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis.
Francisco-Cruz A; Mata-Espinosa D; Estrada-Parra S; Xing Z; Hernández-Pando R
Clin Exp Immunol; 2013 Mar; 171(3):283-97. PubMed ID: 23379435
[TBL] [Abstract][Full Text] [Related]
20. The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs.
Vremec D; Lieschke GJ; Dunn AR; Robb L; Metcalf D; Shortman K
Eur J Immunol; 1997 Jan; 27(1):40-4. PubMed ID: 9021996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
